ArticlePloS one2026
Renal and endothelial biomarkers in Chagas disease in the Brazilian Amazon region: Early indicators of kidney injury and disease progression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) has impact on Amazon public health, where oral transmission is frequently related to acute cases. This peculiarity influences clinical severity and immunological responses, highlighting the need to investigate novel biomarkers for early detection of renal and endothelial dysfunctions, since conventional methods are limited in identifying subclinical renal injury. The aim of this study is to investigate the expression of biomarkers of renal and endothelial injury in acute and chronic CD in the Brazilian Amazon. A cross-sectional study was conducted between 2021 and 2023 at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMTHVD), Manaus, Amazonas, Brazil. Seventy-eight native Amazonian patients diagnosed with CD were evaluated and grouped by disease clinical phase: G1a (acute pre-treatment), G1b (acute post-treatment), G2a (chronic indeterminate), and G2b (chronic cardiac). Blood and urine levels of SYN-1, ANG-2, MCP-1, and NGAL were quantified using ELISA test and correlated with creatinine, urea, proteinuria, and glomerular filtration rate (GFR). Biomarkers were elevated across CD phases, despite routine renal function parameters remaining within normal ranges. Urinary NGAL and MCP-1 levels were significantly elevated in G1, reflecting early renal inflammation. SYN-1 was elevated in patient groups compared with controls, indicating early endothelial damage, while ANG-2 showed high variability with limited subgroup discrimination in G2, suggesting progressive endothelial dysfunction. Overall, G1, especially G1b, exhibited a more severe inflammatory and tissue injury profile, whereas G2 groups were similar to controls. Conventional markers did not correlate with the biomarkers, suggesting their sensitivity in detecting early subclinical injury. The novel biomarkers studied showed an association with different phases of CD and signs of endothelial and renal dysfunction, suggesting potential to aid in the detection of subclinical changes related to the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.